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SHORT REPORT
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Abstract
Spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS) share a common molecular basis: both are
associated with CAG-repeat expansion of ATXN2 and TDP-43-positive neuronal cytoplasmic inclusions. To date, the
two disorders are viewed as clinically distinct with ALS resulting from 30-33 CAG-repeats and SCA2 from >34 CAG-
repeats. We describe a 67-year old with a 32 CAG-repeat expansion of ATXN2 who presented with simultaneous symp-
toms of ALS and SCA2. Our case demonstrates that the clinical dichotomy between SCA2 and ATXN2-ALS is false.
We suggest instead that CAG-repeat expansion length determines the timing of SCA2 clinical symptoms relative to onset
of ALS; consistent with this age of onset of SCA2 but not ATXN2-ALS, is dependent upon expansion length. Review of
the literature and our local cohort provides evidence for occurrence of ALS in late stage SCA2, which may be under-rec-
ognised by clinicians who think of the two diseases as distinct.
Keywords: Risk, neurophysiology, genetics
Introduction
Spinocerebellar ataxia type 2 (SCA2), is a neuro-
degenerative disease primarily of the cerebellum,
brainstem and spinal cord, caused by >34 CAG-
repeat expansion within ATXN2; clinical onset is
between childhood and mid-adulthood (1).
Amyotrophic lateral sclerosis (ALS) features select-
ive degeneration of motor neurons and typically
manifests in late adulthood (2). The genetic basis
of ALS is more diverse than SCA2, however ALS
is associated with 30–33 CAG-repeat expansions
within ATXN2 (3) although penetrance is incom-
plete (4) which is consistent with additional gen-
etic and/or environmental modifiers. Age of onset
in SCA2 is inversely proportional to expansion
length (5) but in ALS it is unrelated (4).
Currently, ALS and SCA2 are considered clinically
distinct.
There is evidence that ALS and SCA2 share a
common molecular pathway to neuronal toxicity.
The pathological hallmark of ALS, including
ATXN2-ALS (6,7), is TDP-43-positive neuronal
cytoplasmic inclusions within motor neurons. Post
mortem study of SCA2 reveals identical TDP-43-
positive neuronal cytoplasmic inclusions but not
within lower motor neurons (8). If the molecular
basis for the two diseases is similar, then the strict
dichotomy in the clinical presentation between
SCA2 and ALS is puzzling because it requires that
longer ATXN2-expansions should be associated
with both amelioration, and increased severity of
the same process, in distinct neuronal populations.
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We propose that the true effect of increased expan-
sion length is not on toxicity but in timing
(Figure 1).
Clinical case
We present a previously well, 67-year old
Caucasian female, with no family history of neuro-
logical disease. She presented with a two month
history of difficulty walking; examination revealed
evidence of cerebellar dysfunction including limb
ataxia and horizontal nystagmus on lateral gaze;
accompanied by evidence of motor neuron degen-
eration including weakness of right hip flexion and
right-sided brisk reflexes. Six months after symp-
tom onset she had developed bilateral wasting of
the dorsal interossei, globally reduced power with
increased muscle tone and brisk reflexes, and dys-
arthria with tongue fasciculations. MRI with sin-
gle-photon emission computed tomography
revealed bilateral atrophy of the cerebellar vermis
and hemispheres. EMG confirmed active and
chronic denervation in three segments, fulfilling
Awaji-Shima electrodiagnostic criteria for ALS.
Genetic testing revealed a heterozygous ATXN2
expansion: she carried an uninterrupted 32 CAG-
repeat expansion and a normal length allele con-
taining 22 repeats with one interruption of CAA at
position 9. No significant mutation was identified
in any other ALS gene contained within our clin-
ical genetic panel (https://www.sheffieldchildrens.
nhs.uk/download/321/ngs/9291/next-generation-
sequencing-v7.pdf). Eighteen months after symp-
tom onset she required noninvasive ventilation for
respiratory failure.
Discussion
To our knowledge, presentation of SCA2 and ALS
symptoms together in the context of an ATXN2
expansion is previously unreported. Based on our
case, we propose that a dichotomy between
ATXN2-ALS and SCA2 is false. We suggest that
expansion length determines the timing of cerebel-
lar degeneration whereas the timing of motor neu-
ron degeneration is similar to ALS more broadly
and independent of expansion length. Patients with
shorter expansions develop motor neuron degener-
ation before late onset cerebellar involvement and
are labeled as ALS. Patients with longer expansions
develop cerebellar degeneration at an early age and
are labeled as SCA2; if they survive until the typical
age of onset for ALS they may develop superim-
posed motor neuron degeneration, as previously
reported (9). The expansion length in our patient is
at the border between the reported ranges for ALS
and SCA2; we propose that she developed both dis-
orders simultaneously because the age of onset for
her cerebellar degeneration determined by her
expansion length, happened to coincide with the
typical age of onset for ALS.
It has been suggested that ATXN2-ALS is
exclusively associated with interrupted CAG-repeat
expansions within ATXN2 versus pure CAG-
repeats in SCA2 (10). In contrast, our case carried
an uninterrupted CAG-repeat expansion but pre-
sented with ALS. Interrupted CAG-repeat expan-
sions may be more stable than pure repeats through
cell division leading to reduced somatic mosaicism
(11). In our framing of the relationship between
expansion length and phenotype this could explain
an overrepresentation of interrupted CAG-repeats
in blood samples from patients presenting initially
with ALS: patients carrying uninterrupted unstable
alleles would be more likely to develop longer
expansion lengths in the CNS, which would in turn
be associated with early presentation of SCA2 prior
to any motor neuron degeneration.
Review of SCA2 neurophysiology literature
supports our hypothesis. Typical SCA2 patients
with longer ATXN2 expansions and young age of
onset do develop muscle denervation consistent
Figure 1. Variability in timing of ALS-symptoms relative to SCA2-symptoms depends on ATXN2-expansion length.
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with motor neuron loss but this occurs >10 years
after ataxia onset (12). We conclude that the typ-
ical SCA2 patient does develop ALS but this may
be masked by ongoing severe ataxia.
We performed a retrospective review of
ATXN2-positive cases diagnosed at our center
(Table 1). The expansion length of our index case
divides patients with longer expansions, who pre-
sented clinically with SCA2 at an earlier age, from
patients with shorter expansions who presented
with pure ALS. The exception is a 62-year old
female with family history of ALS who presented
with ataxia and a 33 CAG-repeat expansion. We
propose that she is at risk of developing ALS; con-
sistent with this she has upper motor neuron signs.
If ATXN2-ALS and SCA2 share a common
molecular pathogenesis then study of differential
toxicity between neuronal populations may lead to
new therapeutic targets. Furthermore clinicians
responsible for SCA2 patients should be aware
that they may develop an ALS-phenotype at the
typical age of onset for ALS.
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ALS F 30 76 None 77 Active and chronic denervation
ALS F 30 47 None 47 Active and chronic denervation
SCA2/ALS* F 32 65 None 66 Active and chronic denervation
SCA2 F 33 56 ALS 60 Normal
SCA2 M 37 50 SCA2 50 Sensory ganglionopathy
SCA2 M 37 40 SCA2 44 Early motor neuropathy
SCA2 M 37 NA NA 71 Sensory ganglionopathy and active denervation
SCA2 F 38 45 SCA2 NA NA
SCA2 M 40 36 SCA2 56 Sensory ganglionopathy
SCA2 F 43 30 None 35 Sensory ganglionopathy
SCA2 F 44 27 NA NA NA
SCA2 M 49 14 SCA2 NA NA
Cases with expansion lengths borderline between typical ALS/SCA2 lengths are highlighted in bold. Index case.
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